Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 45 studies | 47% ± 19% | |
non-classical monocyte | 25 studies | 40% ± 15% | |
classical monocyte | 25 studies | 42% ± 13% | |
monocyte | 21 studies | 38% ± 16% | |
conventional dendritic cell | 19 studies | 35% ± 16% | |
dendritic cell | 13 studies | 44% ± 19% | |
myeloid cell | 13 studies | 42% ± 17% | |
neutrophil | 12 studies | 38% ± 11% | |
microglial cell | 9 studies | 35% ± 16% | |
alveolar macrophage | 8 studies | 42% ± 15% | |
mononuclear phagocyte | 7 studies | 36% ± 10% | |
leukocyte | 6 studies | 29% ± 12% | |
platelet | 4 studies | 27% ± 8% | |
megakaryocyte | 3 studies | 23% ± 4% | |
tissue-resident macrophage | 3 studies | 55% ± 4% | |
intermediate monocyte | 3 studies | 46% ± 22% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 6067.80 | 577 / 578 | 95% | 30.83 | 1096 / 1155 |
breast | 83% | 1178.43 | 383 / 459 | 97% | 20.74 | 1085 / 1118 |
intestine | 84% | 1033.82 | 810 / 966 | 77% | 15.41 | 407 / 527 |
kidney | 69% | 987.10 | 61 / 89 | 87% | 23.36 | 786 / 901 |
adrenal gland | 96% | 1804.07 | 247 / 258 | 53% | 6.59 | 122 / 230 |
bladder | 71% | 1132.05 | 15 / 21 | 73% | 18.48 | 369 / 504 |
thymus | 64% | 646.95 | 418 / 653 | 75% | 10.04 | 453 / 605 |
esophagus | 54% | 608.73 | 776 / 1445 | 84% | 18.08 | 154 / 183 |
ovary | 48% | 426.87 | 87 / 180 | 84% | 17.65 | 362 / 430 |
uterus | 49% | 465.14 | 83 / 170 | 81% | 13.37 | 370 / 459 |
stomach | 46% | 542.17 | 166 / 359 | 81% | 20.07 | 232 / 286 |
brain | 33% | 495.44 | 864 / 2642 | 78% | 21.75 | 553 / 705 |
pancreas | 20% | 186.58 | 66 / 328 | 90% | 25.78 | 160 / 178 |
skin | 14% | 108.42 | 253 / 1809 | 94% | 37.82 | 443 / 472 |
prostate | 59% | 596.02 | 144 / 245 | 49% | 4.25 | 246 / 502 |
spleen | 100% | 6924.90 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 97% | 3063.53 | 1162 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 93% | 2424.80 | 1238 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 14.44 | 39 / 45 |
lymph node | 0% | 0 | 0 / 0 | 86% | 20.17 | 25 / 29 |
peripheral blood | 84% | 41352.86 | 777 / 929 | 0% | 0 | 0 / 0 |
liver | 23% | 226.11 | 52 / 226 | 44% | 5.34 | 177 / 406 |
heart | 54% | 609.39 | 462 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 28% | 2.42 | 22 / 80 |
muscle | 3% | 24.16 | 25 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0050766 | Biological process | positive regulation of phagocytosis |
GO_0001788 | Biological process | antibody-dependent cellular cytotoxicity |
GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
GO_0038094 | Biological process | Fc-gamma receptor signaling pathway |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0030667 | Cellular component | secretory granule membrane |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0019864 | Molecular function | IgG binding |
GO_0019770 | Molecular function | IgG receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | FCGR2A |
Protein name | Fc gamma receptor IIa Low affinity immunoglobulin gamma Fc region receptor II-a (IgG Fc receptor II-a) (CDw32) (Fc-gamma RII-a) (Fc-gamma-RIIa) (FcRII-a) (CD antigen CD32) Fc gamma receptor RIIa3 splice variant |
Synonyms | IGFR2 FCGR2A1 FCG2 CD32 |
Description | FUNCTION: Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens. . |
Accessions | ENST00000536731.5 V9GY83 F5GX41 ENST00000367972.8 [P12318-2] ENST00000483665.6 A0A8V8TPS4 A0A8V8TN30 ENST00000699279.1 V9GY55 A0A346JF56 ENST00000699278.1 ENST00000459885.1 ENST00000467525.5 ENST00000271450.12 [P12318-1] F5GXY9 ENST00000699277.1 P12318 A0A8V8TN00 |